The great tragedy facing the majority of patients with newly diagnosed adenocarcinoma of the pancreas is the persistent high rate of lethality:most newly diagnosed individuals will die within a year.1 Approximately 20% of patients are considered for surgical therapy; however, only about half of these individuals undergo successful resections.2- 4 Surgery remains the only opportunity for cure and can be performed with significant reduction in rates of operative morbidity and mortality, particularly at experienced high-volume centers.5 Use of neoadjuvant strategies in the preoperative setting to improve surgical resectability remain experimental. Adjuvant therapy for the postoperative pancreatic cancer patient has been a highly controversial topic with some strong differences in opinions about the use of adjuvant radiation, chemotherapy, or combined chemoradiation, particularly between investigators in the United States and Europe.6,7
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 10
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.